$VSTM
Verastem Inc

2024 Q2 Form 10-Q Financial Statement

#000155837024007607 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2024
Revenue $10.00M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.22M $10.35M
YoY Change 38.06% 41.25%
% of Gross Profit
Research & Development $18.06M $17.71M
YoY Change 40.09% 47.37%
% of Gross Profit
Depreciation & Amortization $6.000K $6.000K
YoY Change -72.73% -80.0%
% of Gross Profit
Operating Expenses $28.28M $28.06M
YoY Change 39.35% 45.05%
Operating Profit -$18.28M -$28.06M
YoY Change -9.93% 45.05%
Interest Expense $1.138M $1.130M $1.130M
YoY Change 1.52% 46.94% -72.7%
% of Operating Profit
Other Income/Expense, Net -$24.00K -$30.00K
YoY Change -40.0% 328.57%
Pretax Income -$8.256M
YoY Change -66.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.256M -$33.86M
YoY Change -66.0% 115.5%
Net Earnings / Revenue -82.56%
Basic Earnings Per Share -$0.31 -$1.26
Diluted Earnings Per Share -$0.31
COMMON SHARES
Basic Shares Outstanding 25.33M 25.30M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.37M $110.1M
YoY Change -54.46% -0.97%
Cash & Equivalents $83.37M $81.32M
Short-Term Investments $0.00 $28.81M
Other Short-Term Assets $5.450M $7.323M
YoY Change -20.73% -4.76%
Inventory
Prepaid Expenses
Receivables $10.00M
Other Receivables $825.0K
Total Short-Term Assets $99.65M $117.7M
YoY Change -47.54% -1.03%
LONG-TERM ASSETS
Property, Plant & Equipment $46.00K $52.00K
YoY Change 15.0% -16.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.998M $4.575M
YoY Change 24890.0% 12608.33%
Total Long-Term Assets $6.101M $5.865M
YoY Change 239.89% 195.61%
TOTAL ASSETS
Total Short-Term Assets $99.65M $117.7M
Total Long-Term Assets $6.101M $5.865M
Total Assets $105.7M $123.5M
YoY Change -44.85% 2.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.678M $7.449M
YoY Change 46.67% 51.93%
Accrued Expenses $17.20M $17.38M
YoY Change 25.0% 24.72%
Deferred Revenue
YoY Change
Short-Term Debt $526.0K $911.0K
YoY Change -9.15% -9.26%
Long-Term Debt Due $4.926M
YoY Change 1598.62%
Total Short-Term Liabilities $30.35M $26.73M
YoY Change 45.99% 19.53%
LONG-TERM LIABILITIES
Long-Term Debt $35.39M $40.12M
YoY Change -10.94% 1.39%
Other Long-Term Liabilities $0.00 $10.47M
YoY Change -100.0% 119.96%
Total Long-Term Liabilities $35.39M $50.59M
YoY Change -26.61% 14.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.35M $26.73M
Total Long-Term Liabilities $35.39M $50.59M
Total Liabilities $65.74M $77.32M
YoY Change -4.74% 15.93%
SHAREHOLDERS EQUITY
Retained Earnings -$867.0M -$858.8M
YoY Change 11.51% 14.01%
Common Stock $885.9M $883.8M
YoY Change 0.77% 12.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.85M $25.06M
YoY Change
Total Liabilities & Shareholders Equity $105.7M $123.5M
YoY Change -44.85% 2.2%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2024
OPERATING ACTIVITIES
Net Income -$8.256M -$33.86M
YoY Change -66.0% 115.5%
Depreciation, Depletion And Amortization $6.000K $6.000K
YoY Change -72.73% -80.0%
Cash From Operating Activities -$27.57M -$28.31M
YoY Change 38.51% 39.54%
INVESTING ACTIVITIES
Capital Expenditures $7.000K $21.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $29.00M $31.00M
YoY Change 107.14% -3955.72%
Cash From Investing Activities $28.99M $30.98M
YoY Change 107.09% -3953.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -405.0K 846.0K
YoY Change -100.44% -98.08%
NET CHANGE
Cash From Operating Activities -27.57M -28.31M
Cash From Investing Activities 28.99M 30.98M
Cash From Financing Activities -405.0K 846.0K
Net Change In Cash 1.018M 3.518M
YoY Change -98.81% -84.68%
FREE CASH FLOW
Cash From Operating Activities -$27.57M -$28.31M
Capital Expenditures $7.000K $21.00K
Free Cash Flow -$27.58M -$28.33M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
200679000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186264000
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001526119
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25308000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25281000
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-35403
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Verastem, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3269467
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick Street, Suite 500
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
CY2024Q1 dei City Area Code
CityAreaCode
781
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
292-4200
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
VSTM
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25325551
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81316000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77909000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28809000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59220000
CY2024Q1 vstm Grants Receivable Net
GrantsReceivableNet
226000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7323000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6553000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
117674000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
143682000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
997000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1171000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
241000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
241000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4575000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4587000
CY2024Q1 us-gaap Assets
Assets
123539000
CY2023Q4 us-gaap Assets
Assets
149718000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7449000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7184000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17384000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17928000
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
911000
CY2023Q4 vstm Deferred Liabilities
DeferredLiabilities
-327000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
981000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
941000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
26725000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26380000
CY2024Q1 us-gaap Secured Long Term Debt
SecuredLongTermDebt
40123000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
40086000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
270000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
530000
CY2024Q1 vstm Preferred Stock Tranche Liability
PreferredStockTrancheLiability
10200000
CY2023Q4 vstm Preferred Stock Tranche Liability
PreferredStockTrancheLiability
4189000
CY2024Q1 us-gaap Liabilities
Liabilities
77318000
CY2023Q4 us-gaap Liabilities
Liabilities
71185000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25308000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25281000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
883816000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
882248000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
13000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-858753000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-824890000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
25062000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
57374000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123539000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149718000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17707000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12015000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10352000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7329000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
28059000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
19344000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28059000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19344000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1367000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
976000
CY2024Q1 us-gaap Interest Expense
InterestExpense
1130000
CY2023Q1 us-gaap Interest Expense
InterestExpense
769000
CY2024Q1 vstm Income Loss From Preferred Stock Tranche Liability
IncomeLossFromPreferredStockTrancheLiability
-6011000
CY2023Q1 vstm Income Loss From Preferred Stock Tranche Liability
IncomeLossFromPreferredStockTrancheLiability
3430000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33863000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15714000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26832000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16723000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33863000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15714000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-17000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33880000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15708000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
57374000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33863000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-17000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1483000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
25062000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47391000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15714000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1313000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
29000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
33025000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-33863000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-15714000
CY2024Q1 us-gaap Depreciation
Depreciation
6000
CY2023Q1 us-gaap Depreciation
Depreciation
30000
CY2024Q1 vstm Operating Lease Right Of Use Asset And Lease Liability Amortization
OperatingLeaseRightOfUseAssetAndLeaseLiabilityAmortization
-46000
CY2023Q1 vstm Operating Lease Right Of Use Asset And Lease Liability Amortization
OperatingLeaseRightOfUseAssetAndLeaseLiabilityAmortization
-41000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1483000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1313000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
-419000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
-36000
CY2024Q1 vstm Change In Fair Value Of Of Preferred Stock Tranche Liability
ChangeInFairValueOfOfPreferredStockTrancheLiability
6011000
CY2023Q1 vstm Change In Fair Value Of Of Preferred Stock Tranche Liability
ChangeInFairValueOfOfPreferredStockTrancheLiability
-3430000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-31000
CY2024Q1 vstm Increase Decrease In Grants Receivable Net
IncreaseDecreaseInGrantsReceivableNet
-226000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
647000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2089000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
265000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-544000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1045000
CY2024Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-327000
CY2023Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
693000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28307000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20286000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
13804000
CY2024Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
31000000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
13000000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30979000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-804000
CY2023Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
28099000
CY2023Q1 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
14918000
CY2024Q1 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
150000
CY2024Q1 vstm Proceeds From Insurance Premium Financing
ProceedsFromInsurancePremiumFinancing
1298000
CY2023Q1 vstm Proceeds From Insurance Premium Financing
ProceedsFromInsurancePremiumFinancing
1430000
CY2024Q1 vstm Payments On Insurance Premium Financing
PaymentsOnInsurancePremiumFinancing
387000
CY2023Q1 vstm Payments On Insurance Premium Financing
PaymentsOnInsurancePremiumFinancing
426000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
85000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
846000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44050000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3518000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22960000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79076000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75789000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82594000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98749000
CY2023Q1 vstm Issuance Of Preferred Stock Tranche Liability
IssuanceOfPreferredStockTrancheLiability
6940000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">Verastem, Inc. (the “Company”) is a late-stage development biopharmaceutical company, with an ongoing registration directed trial, committed to advancing new medicines for people diagnosed with cancer. The Company’s pipeline is focused on ras sarcoma (“RAS”)/ mitogen activated pathway kinase (“MAPK”) driven cancers, specifically on novel drug candidates that inhibit signaling pathways critical to cancer cell survival and tumor growth, particularly RAF/ MEK inhibition and FAK inhibition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company’s most advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (“LGSOC”), non-small cell lung cancer (“NSCLC”), pancreatic cancer, colorectal cancer (“CRC”), and thyroid. The Company believes that avutometinib may be beneficial as a therapeutic as a single agent or when used together in combination with defactinib, other pathway inhibitors or other current and emerging standard of care treatments in cancers that do not adequately respond to currently available therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of Verastem Securities Company and Verastem Europe GmbH, wholly-owned subsidiaries of the Company. All financial information presented has been consolidated and includes the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the risks associated with other life science companies, including, but not limited to, possible failure of preclinical testing or clinical trials, competitors developing new technological innovations, inability to obtain marketing approval of the Company’s product candidates, avutometinib and defactinib, market acceptance and commercial success of the Company’s product candidates, avutometinib and defactinib, following receipt of regulatory approval, and, protection of proprietary technology and the continued ability to obtain adequate financing to fund the Company’s future operations. If the Company does not obtain marketing approval and successfully commercialize its product candidates, avutometinib and defactinib, following regulatory approval, it will be unable to generate product revenue or achieve profitability and may need to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, the Company had cash, cash equivalents, and investments of $110.1 million. In accordance with applicable accounting standards, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the date of the issuance of these condensed consolidated financial statements. The Company anticipates operating losses may continue for the foreseeable future since the Company does not yet have regulatory approval to sell any of its product candidates, and the Company continues to incur operating costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial readiness activities.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern for 12 months after the date the condensed consolidated financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to finance its operations with its existing cash, cash equivalents and investments, through potential future milestones and royalties received pursuant to the asset purchase agreement dated August 10, 2020, between the Company and Secura (the “Secura APA”), through the loan and security agreement with Oxford Finance LLC (“Oxford”), or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, future offerings of its equity, or the incurrence of debt. However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the U.S. Food &amp; Drug Administration (the “FDA”) or foreign regulatory authorities.  Therefore, there is substantial doubt about the Company’s ability to continue as a going concern.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 30, 2023, the Company filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 at a ratio of <span style="-sec-ix-hidden:Hidden_6ZF3hHCxvU6mclqVzHbIbQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-12</span></span> (the “Reverse Stock Split”), as authorized at the Company’s 2023 annual meeting of stockholders held on May 15, 2023. The Company effected the Reverse Stock Split on May 31, 2023. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the Reverse Stock Split, as adjusted by the ratio of <span style="-sec-ix-hidden:Hidden_6IUECogWzEaDaJpbGBnKrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> share of common stock for every 12 shares of common stock, multiplied by the applicable fraction of a share. The number of shares of common stock that the Company is authorized to issue remains at 300,000,000 shares and the par value of its common stock remains unchanged at $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has retroactively restated the share and per share amounts in the unaudited condensed consolidated financial statements for the three months ended March 31, 2023, to give retroactive effect to the Reverse Stock Split.<span style="background:#ffffff;"> Proportionate adjustments were made to the per share exercise price and number of shares of common stock issuable under all outstanding stock options, convertible notes and preferred stock. In addition, proportionate adjustments have been made to the number of shares of common stock issuable upon vesting of the restricted stock units and the number of shares of common stock reserved for the Company’s equity incentive compensation plans. </span>The condensed consolidated statements of convertible preferred stock and stockholders’ equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split for the three months ended March 31, 2023. </p>
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
110100000
CY2024Q1 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of March 31, 2024, the Company’s cash, cash equivalents and investments were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.
CY2022Q2 vstm Grant Awarded Amount
GrantAwardedAmount
3800000
CY2022Q3 vstm Proceeds From Grants
ProceedsFromGrants
500000
CY2024Q1 vstm Proceeds From Grants
ProceedsFromGrants
3500000
CY2024Q1 vstm Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
1400000
CY2023Q1 vstm Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
100000
CY2024Q1 vstm Grants Receivable Net
GrantsReceivableNet
200000
CY2023Q4 vstm Deferred Liabilities
DeferredLiabilities
-300000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
2
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81316000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77909000
CY2024Q1 vstm Restricted Cash Noncurrent And Prepaid Expenses And Other Current Assets
RestrictedCashNoncurrentAndPrepaidExpensesAndOtherCurrentAssets
1278000
CY2023Q4 vstm Restricted Cash Noncurrent And Prepaid Expenses And Other Current Assets
RestrictedCashNoncurrentAndPrepaidExpensesAndOtherCurrentAssets
1167000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82594000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79076000
CY2024Q1 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2022Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2022Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q1 us-gaap Interest Receivable
InterestReceivable
100000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
28809000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
4000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
8896000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000
CY2024Q1 vstm Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
7319000
CY2023Q4 vstm Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
6518000
CY2024Q1 vstm Accrued Contract Manufacturing Expenses Current
AccruedContractManufacturingExpensesCurrent
2384000
CY2023Q4 vstm Accrued Contract Manufacturing Expenses Current
AccruedContractManufacturingExpensesCurrent
2010000
CY2024Q1 vstm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1276000
CY2023Q4 vstm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1043000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2531000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4796000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
889000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
637000
CY2024Q1 vstm Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
1544000
CY2023Q4 vstm Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
1078000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
316000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
316000
CY2024Q1 vstm Accrued Commercialization Costs Current
AccruedCommercializationCostsCurrent
437000
CY2023Q4 vstm Accrued Commercialization Costs Current
AccruedCommercializationCostsCurrent
453000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
688000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1077000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17384000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17928000
CY2023Q1 us-gaap Debt Instrument Covenant Description
DebtInstrumentCovenantDescription
The Loan Agreement contains no financial covenants.
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2024Q1 vstm Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
782000
CY2023Q4 vstm Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
661000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
659000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
575000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
40123000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
40086000
CY2024 vstm Contractual Interest Expense
ContractualInterestExpense
943000
CY2023Q1 vstm Contractual Interest Expense
ContractualInterestExpense
632000
CY2024 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
66000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
58000
CY2024 vstm Amortization Of Final Payment Fee
AmortizationOfFinalPaymentFee
121000
CY2023Q1 vstm Amortization Of Final Payment Fee
AmortizationOfFinalPaymentFee
79000
CY2024 us-gaap Interest Expense
InterestExpense
1130000
CY2023Q1 us-gaap Interest Expense
InterestExpense
769000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15000000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5000000
CY2024Q1 vstm Long Term Debt Maturities Aggregate Principal Due
LongTermDebtMaturitiesAggregatePrincipalDue
40000000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1300000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
221000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
221000
CY2024Q1 us-gaap Lease Cost
LeaseCost
221000
CY2023Q1 us-gaap Lease Cost
LeaseCost
221000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
268000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
262000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.146
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
813000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
546000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1359000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
108000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1251000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7625682
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7217024
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Other Commitment
OtherCommitment
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-007607-index-headers.html Edgar Link pending
0001558370-24-007607-index.html Edgar Link pending
0001558370-24-007607.txt Edgar Link pending
0001558370-24-007607-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vstm-20240331.xsd Edgar Link pending
vstm-20240331x10q.htm Edgar Link pending
vstm-20240331xex31d1.htm Edgar Link pending
vstm-20240331xex31d2.htm Edgar Link pending
vstm-20240331xex32d1.htm Edgar Link pending
vstm-20240331xex32d2.htm Edgar Link pending
vstm-20240331xex99d1.htm Edgar Link pending
vstm-20240331xex99d1001.jpg Edgar Link pending
vstm-20240331_lab.xml Edgar Link unprocessable
vstm-20240331_def.xml Edgar Link unprocessable
vstm-20240331_pre.xml Edgar Link unprocessable
vstm-20240331x10q_htm.xml Edgar Link completed
vstm-20240331_cal.xml Edgar Link unprocessable